SCREENING EXAMINATION FOR CERVICAL CANCER

Cervical cancer is one of the most common malignant neoplasms among women, and in more than 90% of cases, it is caused by cancer-causing strains of the Human Papillomavirus (HPV).

The presence of the Human Papillomavirus (HPV) does not mean that a woman has cancer. HPV is a very common virus that is sexually transmitted. Almost all people become infected with this virus at some point in their lives, but the body often clears it on its own. However, certain high-risk strains can persist in the body and require dynamic surveillance to prevent complications.

Cervical cancer ranks fifth among malignancies in women in Armenia, and second in terms of mortality rate. On average, around 250 new cases are registered every year, almost half of which result in a fatal outcome. The main reason for this is the late detection of the disease, as it often progresses for a long time without pronounced symptoms.

The screening is intended for women aged 30 to 60. Exceptions include women who have never been sexually active, women whose cervix is absent post-surgery, and women diagnosed with cervical cancer or precancer.

The insurance package includes the detection of Human Papillomavirus (HPV) using the PCR method, which is performed with WHO-approved, FDA-certified high-quality tests, ensuring high reliability of testing. The package also includes colposcopic examination and, if necessary, subsequent additional examinations and treatment.